Gennex Laboratories quarterly results and financials

Gennex Laboratories (BSE 531739)₹8.96+3.46%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Gennex Laboratories reported sales of ₹39.73 Cr, up 16.5% from Jun 2025, and net profit of ₹4.66 Cr, down 6.8% year on year. For the year to Mar 2026, sales were ₹173 Cr and net profit ₹20.97 Cr.

Sales (Jun 2026): ₹39.73 Cr
Net profit (Jun 2026): ₹4.66 Cr
Sales (FY Mar 2026): ₹173 Cr
Net profit (FY Mar 2026): ₹20.97 Cr
EPS (Jun 2026): ₹0.19
Borrowings (Mar 2026): ₹78.88 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Gennex Laboratories quarterly results

₹ crore unless stated; each column is a quarter.

Gennex Laboratories Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	18.13	21.34	35.43	28.23	33.31	39.87	40.24	34.09	39.21	42.85	60.82	39.73
Expenses	12.46	16.66	29.37	24.18	26.02	32.96	38.43	29.21	31.85	34.54	55.23	35.59
Operating Profit	5.75	4.79	6.24	4.21	7.44	7.13	2.01	5.05	7.54	8.54	5.87	4.36
OPM %	31.8%	22.5%	17.7%	14.9%	22.4%	17.9%	5.1%	14.9%	19.3%	20.0%	9.7%	11.0%
Other Income	0.00	0.00	0.00	2.48	0.00	0.00	3.69	2.29	0.00	−0.31	1.03	2.02
Interest	0.79	0.84	0.74	0.74	0.23	0.85	1.21	0.99	1.04	1.12	1.09	0.58
Depreciation	1.04	0.46	0.24	0.46	1.12	0.51	0.55	0.51	0.48	0.53	1.17	0.89
Profit before tax	3.95	3.51	5.31	5.52	6.14	5.82	3.97	5.88	6.07	6.65	4.66	4.93
Tax %	22.5%	21.3%	15.3%	15.5%	12.3%	12.9%	22.2%	14.5%	9.1%	9.8%	4.5%	5.1%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	−0.11	0.00	0.00	−0.28	−0.30	0.00
Net Profit	3.06	2.75	4.49	4.65	5.37	5.05	3.06	5.00	5.50	5.99	4.45	4.66
EPS (Rs)	0.18	0.16	0.21	0.20	0.22	0.21	0.11	0.21	0.22	0.23	0.16	0.19

Gennex Laboratories profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Gennex Laboratories Profit and loss
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	41.92	43.91	55.81	55.84	59.86	60.86	65.79	86.78	138	173	183
Expenses	37.16	42.13	52.15	52.22	53.21	56.22	61.18	70.27	121	150	157
Operating Profit	4.99	1.99	3.99	2.99	6.98	4.98	4.98	16.95	16.94	21.92	26.31
OPM %	11.1%	5.0%	7.0%	6.0%	11.0%	9.1%	7.0%	20.1%	12.1%	13.1%	14.4%
Other Income	0.00	1.01	1.01	1.01	0.00	1.01	4.01	5.01	10.02	8.02	2.74
Interest	1.01	1.01	1.01	1.01	1.01	1.01	1.01	3.01	4.02	4.01	3.83
Depreciation	1.01	0.99	1.01	1.01	0.99	1.01	1.01	2.01	2.01	3.01	3.07
Profit before tax	3.01	1.01	2.99	2.99	5.01	4.99	5.99	16.01	21.01	22.99	22.31
Tax %	13.0%	42.0%	26.0%	27.0%	20.0%	23.0%	23.0%	20.0%	15.0%	10.0%	—
Exceptional items	0.00	0.02	0.00	0.07	−0.27	0.00	0.05	0.45	−0.13	−0.55	−0.58
Net Profit	2.99	0.99	1.99	1.99	3.99	3.99	4.99	12.97	17.97	20.97	20.60
EPS (Rs)	0.15	0.05	0.13	0.11	0.22	0.22	0.29	0.59	0.81	0.77	0.80
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Gennex Laboratories balance sheet

₹ crore, at each year end.

Gennex Laboratories Balance sheet
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12.98	12.99	12.98	12.99	12.98	12.98	17.98	22.98	22.95	23.93
Reserves	17.96	18.95	20.95	22.92	26.92	30.90	61.87	148	164	197
Borrowings	4.01	2.01	5.00	5.01	7.02	10.02	1.01	6.01	10.01	78.88
Other Liabilities	13.93	15.93	12.94	15.96	11.93	13.93	50.81	53.87	58.71	46.78
Total Liabilities	48.88	49.88	51.87	56.88	58.85	67.83	132	229	255	348
Fixed Assets	15.97	15.97	15.97	14.97	13.96	13.96	73.82	55.82	59.81	60.85
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.99	5.01	12.99
Investments	6.99	6.99	6.99	6.99	7.01	7.01	0.00	0.00	0.00	0.00
Other Assets	25.92	27.92	28.91	34.92	37.88	47.86	58.85	172	190	274
Inventories	2.99	1.99	4.98	6.97	4.98	7.97	15.95	24.91	35.89	53.78
Trade receivables	9.99	9.98	9.99	5.99	8.99	10.98	8.99	17.98	13.98	43.98
Cash & equivalents	0.99	0.99	2.99	0.99	0.99	7.97	14.96	60.83	55.80	51.84
Total Assets	48.88	49.88	51.87	56.88	58.85	67.83	132	229	255	348

Gennex Laboratories cash flow

₹ crore, for each year.

Gennex Laboratories Cash flow
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	0.00	3.01	2.01	−2.01	−1.01	12.05	24.08	−47.18	−11.04	−64.28
Cash from investing activity	−0.99	−0.99	−0.99	0.00	0.00	−1.99	−37.95	18.99	0.99	−5.01
Cash from financing activity	1.01	−2.01	1.01	0.00	2.01	−2.01	21.02	74.10	5.01	65.11
Net cash flow	0.00	0.00	2.01	−2.01	0.00	8.03	6.02	46.12	−5.01	−3.01
Capex	1.01	0.77	1.03	0.30	0.09	1.60	39.81	0.00	8.96	11.95
Free cash flow	−0.99	1.99	0.99	−1.99	−1.99	9.99	−15.97	−30.97	−19.98	−75.86
CFO / OP %	12.9%	189.9%	55.0%	−52.1%	1.0%	241.9%	505.0%	−274.0%	−45.1%	−274.1%

Gennex Laboratories ratios

Working-capital days and returns, by year.

Gennex Laboratories Ratios
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	90	87	68	41	55	67	52	75	37	92
Inventory days	43	31	57	78	50	72	139	184	133	153
Days payable	140	162	89	87	60	73	64	112	50	59
Cash conversion cycle	−8	−44	37	33	45	66	128	147	121	186
Working capital days	75	76	57	88	109	88	24	256	215	296
ROCE %	—	6.0%	11.0%	8.0%	14.0%	12.0%	11.0%	14.1%	13.0%	11.0%

Gennex Laboratories: frequently asked questions

What are the latest quarterly results of Gennex Laboratories?

For the Jun 2026 quarter, Gennex Laboratories reported sales of ₹39.73 Cr, up 16.5% year on year and net profit of ₹4.66 Cr, down 6.8% year on year. The operating margin was 11.0%.

What is the annual revenue of Gennex Laboratories?

Gennex Laboratories' sales for the year to Mar 2026 were ₹173 Cr; over the last twelve months they were ₹183 Cr.

What is the net profit of Gennex Laboratories?

Net profit for the year to Mar 2026 was ₹20.97 Cr, and ₹20.60 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.80.

How much debt does Gennex Laboratories have?

Gennex Laboratories reported borrowings of ₹78.88 Cr at Mar 2026, against cash and equivalents of ₹51.84 Cr.

What is the free cash flow of Gennex Laboratories?

Cash from operations was −₹64.28 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹75.86 Cr.

Loading…